Acoltremon: The first TRPM8 agonist approved for the treatment of dry eye disease
{{output}}
Dry eye disease (DED) is a common ocular surface disorder that markedly affects the quality of life (QoL) of patients. Conventional treatments for DED were unable to meet current medical needs. Acoltremon, a transient receptor potential melastatin 8 (TRPM8) ag... ...
